Penn Medicine's Jakub Svoboda describes a CD19 CAR-T that has been armored with IL18 and is being studied for CAR-T relapse patients
He will be presenting final data from a 21 patient NHL cohort at the 2024 ASCO Annual Meeting in June.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Popular
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
​
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
​
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
​
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A
bottom of page